Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05459272
Other study ID # URI-AQ-SUEFORT-2021
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 10, 2022
Est. completion date October 30, 2023

Study information

Verified date May 2023
Source Uriach Consumer Healthcare
Contact Anna Fortuny
Phone +34 938 630 311
Email anna.fortuny@uriach.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, double-blind, placebo-controlled clinical trial on the ability of a dietary supplement containing melatonin and herbal products to improve sleep quality in subjects with insomnia problems with a 15-day follow-up period.


Description:

This is a single-centre clinical trial on a dietary supplement with a 15-day follow-up period. The investigators will include patients of legal age with DSM-5 diagnostic criteria for insomnia, without other sleep disorders. The study will begin at baseline visit (day 0), when the inclusion and exclusion criteria will be confirmed and patient will sign the informed consent form. Information related to sleeping disorder will be collected and actigraphy device will be delivered to the patient. Patient will wear the device during 14 days. After 7 days of wearing the device, patient will return to the follow-up visit (visit 1). The actigraph data will be downloaded and the treatment will be dispensed to the patient. Regimen will consist of taking one tablet per day of the product (dietary supplement or placebo) 30 minutes before bedtime during the following 7 days and will continue to wear the device. At day 15 (final visit) patient will return the actigraph and clinical and safety data will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients of legal age with DSM-5(*) diagnostic criteria for insomnia assessed from the Sleep Test responses (ST: 5-item questionnaire modified from the "Oviedo Sleep Questionnaire"). - Patients with insomnia of the following types: sleep onset insomnia (> 30 minutes of sleep latency), maintenance insomnia (frequent awakenings or inability to fall asleep after awakening) or mixed insomnia - Patients who are not on treatment or have not taken any dietary supplements or hypnotics for insomnia, or any other psychoactive drug in the past week. - Patients able to understand the implications of the study and who demonstrate this by voluntarily signing the informed consent DSM-5 diagnostic criterion for insomnia: A. A predominant complaint of dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms: 1. Difficulty initiating sleep. (In children, this may manifest as difficulty initiating sleep without caregiver intervention.) 2. Difficulty maintaining sleep, characterized by frequent awakenings or problems returning to sleep after awakenings. (In children, this may manifest as difficulty returning to sleep without caregiver intervention.) 3. Early-morning awakening with inability to return to sleep. B. The sleep disturbance causes clinically significant distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning. C. The sleep difficulty occurs at least 3 nights per week. D. The sleep difficulty is present for at least 3 months. E. The sleep difficulty occurs despite adequate opportunity for sleep. F. The insomnia is not better explained by and does not occur exclusively during the course of another sleep-wake disorder (e.g., narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia). G. The insomnia is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication). H. Coexisting mental disorders and medical conditions do not adequately explain the predominant complaint of insomnia. Exclusion Criteria: - Pregnant or nursing women - Patients with other sleep disorders: narcolepsy, obstructive apnea, circadian rhythm disorder, parasomnias - Patients with active psychiatric disorders or cognitive impairment - Patients with serious diseases that, in the physician's opinion, could interfere with the results of the study or disadvise their participation in it - Patients who do not give their written consent - Patients with known hypersensitivity or intolerance to any of the active ingredients or components of the dietary supplement or placebo.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Aquilea Sueno Forte
The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa). Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14).
Other:
Placebo
The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients. Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14).

Locations

Country Name City State
Spain Instituto de Medicina del Sueño Alboraya Valencia

Sponsors (1)

Lead Sponsor Collaborator
Uriach Consumer Healthcare

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mean sleep latency (SL) Change in sleep latency comparing mean sleep latency during first week (without treatment) with mean sleep latency during second week (with treatment), assessed by actigraphy. At the end of study (Day 15)
Primary Change in total sleep time (TST) Change in total sleep time comparing mean total sleep time during first week (without treatment) with mean total sleep time during second week (with treatment), assessed by actigraphy. At the end of study (Day 15)
Primary Change in number of awakenings at night, assessed by actigraphy Change in number of awakenings at night comparing average number of awakenings at night during first week (without treatment) with average number of awakenings at night during second week (with treatment), assessed by actigraphy. At the end of study (Day 15)
Primary Change in distribution of sleep and awake periods throughout the day (DSW) Changes in distribution of sleep and awake periods throughout the day (DSW) comparing the DSW during first week (without treatment) with DSW during second week (with treatment), assessed by actigraphy. At the end of study (Day 15)
Secondary Type of insomnia Proportion of patients with each type of insomnia: conciliation insomnia, maintenance insomnia or mixed insomnia At the beginning
Secondary Time from insomnia onset Time from insomnia problems onset (weeks, months) At the beginning (Day 0)
Secondary Symptoms secundary to insomnia Mean of number of symptoms caused by insomnia: fatigue o discomfort, day time sleepiness, lack of memory or concentration, low performance, lack of energy, headache, gastrointestinal symptoms, irritability, concern about sleep. At the beginning (Day 0)
Secondary Lack of memory or concentration secundary to insomnia Percentage of patients with lack of memory or concentration caused by insomnia. At the beginning (Day 0)
Secondary Fatigue o discomfort secundary to insomnia Percentage of patients with fatigue o discomfort caused by insomnia. At the beginning (Day 0)
Secondary Day time sleepiness secundary to insomnia Percentage of patients with day time sleepiness caused by insomnia. At the beginning (Day 0)
Secondary Low performance secundary to insomnia Percentage of patients with low performance caused by insomnia. At the beginning (Day 0)
Secondary Lack of energy secundary to insomnia Percentage of patients with lack of energy caused by insomnia. At the beginning (Day 0)
Secondary Headache secundary to insomnia Percentage of patients with headache caused by insomnia. At the beginning (Day 0)
Secondary Gastrointestinal symptoms secundary to insomnia Percentage of patients with gastrointestinal symptoms caused by insomnia. At the beginning (Day 0)
Secondary Irritability secundary to insomnia Percentage of patients with irritability caused by insomnia. At the beginning (Day 0)
Secondary Concern about sleep secundary to insomnia Percentage of patients with concern about sleep caused by insomnia. At the beginning (Day 0)
Secondary Change in Pittsburgh Sleep Quality Index (PSQI) score Change in PSQI score comparing score obtained at the beginning (day 0) and at the end of the study (day 15) At the end of study (Day 15)
Secondary Change in Insomnia Severity Index (ISI) score Change in Insomnia Severity Index (ISI) score comparing score obtained at the beginning (day 0) and at the end of the study (day 15) At the end of study (Day 15)
Secondary Change in quality of life score (SF-12) Change in quality of life score (SF-12) comparing score obtained at the beginning (day 0) and at the end of the study (day 15) At the end of study (Day 15)
Secondary Change in mean sleep latency (SL) according to electronic sleep diary Change in mean of SL (time it takes to fall asleep when you go to bed) comparing mean SL during first week (without treatment) with mean SL during second week (with treatment), according to electronic sleep diary At the end of study (Day 15)
Secondary Change in number of awakenings at night, according to electronic sleep diary Change in number of awakenings at night comparing mean SL during first week (without treatment) with mean SL during second week (with treatment), according to electronic sleep diary At the end of study (Day 15)
Secondary Change in total minutes awake out of bed, according to electronic sleep diary Change in mean of total minutes awake out of bed comparing mean of total minutes during first week (without treatment) with mean of total minutes during second week (with treatment), according to electronic sleep diary At the end of study (Day 15)
Secondary Change in total minutes awake intrasleep, according to electronic sleep diary Change in mean of total minutes awake intrasleep comparing mean of total minutes during first week (without treatment) with mean of total minutes during second week (with treatment), according to electronic sleep diary At the end of study (Day 15)
Secondary Tolerability and safety of the product Number of participants with incidence of treatment-related adverse effects and adverse reaction as a Measure of Safety and Tolerability At the end of study (Day 15)
Secondary Compliance Number of days taking the treatment before going to sleep At the end of study (Day 15)
Secondary Patient satisfaction Patient satisfaction on the efficacy and tolerability of treatment with the dietary supplement, using 5-point Likert scales ((0=very dissatisfied, 1=dissatisfied, 2=indifferent, 3=satisfied, 4=very satisfied) At the end of study (Day 15)
See also
  Status Clinical Trial Phase
Completed NCT02188498 - Electrocardiography Data Analysis in Sleep Disorders
Completed NCT00990106 - Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD) N/A
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00163670 - The Impact of Sleep Disorders on Motor Vehicle Accidents N/A
Completed NCT00256685 - Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Phase 3
Completed NCT00203827 - Pediatric Sleep Questionnaire: Use for Collection of Clinical Data N/A
Completed NCT00174174 - Provigil (Modafinil) Study by Taiwan Biotech Co. N/A
Terminated NCT00750919 - Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) Phase 3
Completed NCT02939586 - The Effect of Haemodialysis in Sleep Apnoea N/A
Completed NCT03075241 - Z-Drugs for Sleep Disorders in Alzheimer's Disease Phase 3
Completed NCT03055156 - Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms N/A
Completed NCT02585609 - Sleep Quality in Patients With Advanced Cancer N/A
Completed NCT02156128 - Subjective Memory Complaints, Objective Memory Performance and Cognitive Training N/A
Completed NCT01929447 - Evaluation of WP200 With the Unified Probe (WP200U) N/A
Completed NCT01906866 - Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities Phase 3
Completed NCT01528462 - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed NCT01256983 - Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation Phase 0
Completed NCT01220401 - Efficacy of a Brief Nightmare Treatment for Veterans N/A
Not yet recruiting NCT00749814 - Sleep Disturbances in Hospitalized Children Phase 4
Completed NCT00518986 - Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Phase 4